Galderma Appoints Luigi La Corte as New CFO Effective May 2026
The “Skin Story” Evolution: From Joint Venture to a $46 Billion Powerhouse
Galderma’s trajectory is a case study in strategic maturation. Founded in 1981 as a joint venture between Nestlé and L’Oréal, the company spent decades as a specialized subsidiary before its 2019 carve-out by an EQT-led consortium. Its March 2024 listing on the SIX Swiss Exchange (SIX: GALD) marked the birth of the world’s leading “pure-play” dermatology powerhouse. As of mid-February 2026, the company commands a formidable market capitalization of $46.4 billion, with its stock trading at $197.75.
Today, Galderma operates across 90 countries, delivering a science-based portfolio that bridges the gap between medical rigor and consumer desire. However, as the company sustains record-breaking growth, a critical question faces the board: How does a global leader manage a high-stakes leadership transition without breaking its stride?
A “Smooth and Orderly” Succession in a High-Growth Era
On February 16, 2026, Galderma announced a meticulously planned transition for its highest financial office. Luigi La Corte will join the company on April 1, 2026, and officially assume the role of Chief Financial Officer (CFO) on May 1. To ensure continuity, outgoing CFO Thomas Dittrich—who has steered the company’s financial strategy since 2019—will remain through the end of Q2 2026.
For a company that has been public for less than two years, this three-month overlap is a strategic necessity. It allows for the seamless closing of the 2025 fiscal reporting cycle while integrating new leadership into the 2026 expansion plans.
“Luigi La Corte is an accomplished financial leader with deep experience across global healthcare and consumer organizations. I am delighted to welcome him to the Executive Committee and look forward to working with him closely as we continue to execute our Integrated Dermatology Strategy and extend our category leadership… I would also like to thank Thomas for his commitment to ensuring a seamless transition and his many contributions to Galderma.” — Flemming Ørnskov, M.D., MPH, CEO of Galderma
The “Triple-Threat” Strategist: Who is Luigi La Corte?
An Italian national and a Fellow of the Chartered Institute of Management Accountants (CIMA), La Corte brings more than 30 years of international financial leadership to Galderma. Most recently, he served as CFO of Recordati S.p.A. (2019–2025), where he also held a seat on the Board of Directors.
His background offers a rare “triple-threat” combination of industry exposure that perfectly mirrors Galderma’s three-pillar portfolio:
* Pharmaceutical Discipline: Senior leadership roles at GlaxoSmithKline and AstraZeneca.
* Consumer Brand Agility: Executive experience at PepsiCo, Procter & Gamble, and pladis Food Group.
* Strategic Consulting: Foundational experience at Bain & Company.
This blend of “Healthcare + Consumer + Strategy” is essential for managing the distinct dynamics of Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology.
Inheriting a $3.7 Billion Momentum
Unlike many CFO transitions necessitated by crisis, La Corte inherits a balance sheet at peak performance. According to the nine-month 2025 report, Galderma delivered record net sales of $3.737 billion, a 15.0% year-on-year surge at constant currency.
This momentum has allowed the company to raise its full-year 2025 guidance significantly, targeting net sales growth of 17.0–17.7% and Core EBITDA margins between 23.1% and 23.6%. Outgoing CFO Thomas Dittrich, reflecting on the transition, called his tenure the “most impactful transformation and growth journey” of his career.
The “Blockbuster” Pipeline as a Financial Catalyst
La Corte’s primary mandate will be to scale the financial architecture behind Galderma’s “pipeline within an asset” strategy. The current growth is anchored by two major catalysts:
1. Nemluvio (nemolizumab): This asset delivered $263 million in the first nine months of 2025. Beyond its FDA approval, it has achieved global milestones including TGA approval in Australia and a NICE recommendation in the UK. To maximize this asset, Galderma has initiated Phase II trials for systemic sclerosis and chronic pruritus of unknown origin (CPUO).
2. Relfydess: Now launched in 17 international markets, this ready-to-use liquid neuromodulator is a volume driver. Galderma has specifically initiated technology transfers to secure “double-sourcing” capacity in the U.S.—a critical risk mitigation strategy to ensure supply chain resilience for what is expected to be a global blockbuster.
Strategic Pivot to a Global Powerhouse
Galderma is currently executing a massive geographical shift toward the U.S. market, which now accounts for approximately 40% of its net sales. To protect and grow this concentrated revenue stream, the company recently established its U.S. headquarters in Miami and committed over $650 million to U.S. manufacturing through 2030.
CEO Flemming Ørnskov’s shift in rhetoric—from “category leader” to “undisputed dermatology powerhouse”—is backed by these heavy capital investments. La Corte’s arrival marks the financial maturation of this ambition, moving the company from a high-growth IPO story to a stabilized, investment-grade global leader.
Conclusion: The Road to May 2026
As Galderma prepares for the May 2026 transition, it does so from a position of undisputed strength. The road ahead requires a CFO who can balance the long-term R&D cycles of therapeutic dermatology with the fast-moving retail cycles of aesthetics and skincare.
The success of this transition will serve as a bellwether for the industry. It leaves investors with a final, provocative thought: Can the fusion of rigid pharmaceutical discipline and consumer-centric innovation fundamentally redefine the global standards for skin health by the end of this decade?
Leave a Reply